Concepedia

Author

Jay Mei

University of MünsterORCID

Also Known As

J M Mei, J Mei, J. M. Mei, J. Mei, J.M. Mei, Jay M. Mei, Jay Mei

95

Publications

2K

Citations

18

H-Index

45

Concepts

All Affiliations

University of MünsterSapienza University of RomeBristol-Myers Squibb (Switzerland)Johnson & Johnson (United States)Cleveland Clinic
JM

About

Jay Mei is an author at University of Münster specializing in medicine, hematology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

450

2

Health Sciences

3

3

85

3

Natural Sciences

3

3

336

4

Engineering

1

1

13

5

Biochemistry

1

1

285

Jay Mei

×

24

Publications

1.8K

Citations

17

H-Index

YearCitations

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

Antonio Palumbo, Roman Hájek, Michel Delforge,

New England Journal of Medicine

2012

737

Proline oxidase, encoded by p53-induced gene-6, catalyzes the generation of proline-dependent reactive oxygen species.

Steven P. Donald, Xiao Ya Sun, Chien-an A. Hu,

PubMed

2001

285

Cloning, Expression, and Functional Characterization of Human Cyclooxygenase-1 Splicing Variants: Evidence for Intron 1 Retention

Sui‐Po Zhang, Tasha L. Reitz, Jay Mei,

Journal of Pharmacology and Experimental Therapeutics

2005

78

Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial

Eytan M. Stein, Courtney D. DiNardo, Jessica K. Altman,

Blood

2015

71

Differential expression of prostaglandin endoperoxide H synthase-2 and formation of activated β-catenin–LEF-1 transcription complex in mouse colonic epithelial cells contrasting in Apc

Jay Mei, Norman G. Hord, Dolores Winterstein,

Carcinogenesis

1999

56

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone In Patients ≥ 65 Years with Newly Diagnosed Multiple Myeloma (NDMM): Continuous Use of Lenalidomide Vs Fixed-Duration Regimens

Antonio Palumbo, Michel Delforge, John Catalano,

Blood

2010

55

Matrix metalloproteinase(s) mediate(s) NO-induced dissociation of beta-catenin from membrane bound E-cadherin and formation of nuclear beta-catenin/LEF-1 complex

Jay Mei

Carcinogenesis

2002

53

A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial

Jian Hou, Xin Du, Jie Jin,

Journal of Hematology & Oncology

2013

51

A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma.

Antonio Palumbo, Meletios Α. Dimopoulos, Michel Delforge,

Blood

2009

48

Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Jennifer R. Brown, Wael A. Harb, Brian T. Hill,

Blood

2013

45

Page 1